Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fitscha

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Journal of Cardiovascular Pharmacology|May 1, 1985
Transient drug-induced myocardial dysfunction is not ameliorated by PGI2 in dogsP Fitscha, G Krumpl, R Seitelberger, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 1, 1989
Beneficial effect of long-term PGE1-treatment in left ventricular heart failureI Virgolini, J Kaliman, P Fitscha, et al.
Prostaglandins|June 1, 1987
Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivoH Sinzinger, T Zidek, P Fitscha, et al.
Thrombosis Research|May 1, 1994
Isradipine decreases arterial thrombogenicity in rabbits. A morphometric and radioisotopic studyP Fitscha, A Keiler, J O'Grady, et al.
Fortschritte Der Medizin|February 3, 1977
[Pindolol as an antihypertensive agent]W F Pinggera, P Fitscha, H K Stummvoll, et al.
Prostaglandins, Leukotrienes, and Medicine|March 1, 1985
The prostacyclin synthesis stimulating plasma factor is unchanged during acute angina pectorisH Sinzinger, J Kaliman, P Fitscha, et al.
Prostaglandins|July 1, 1991
Intravenous prostacyclin (PGI2) infusion to 108 patients with ischaemic peripheral vascular disease: phase II-open studyI Virgolini, P Fitscha, K Weiss, et al.
Blood Pressure. Supplement|January 1, 1994
Isradipine increases platelet--low-density lipoprotein binding: evidence from ex-vivo studies in humansP Schmid, C Pirich, P Fitscha, et al.
European Journal of Clinical Pharmacology|January 1, 1997
Prostaglandin E1 decreases human arterial accumulation of radiolabeled apo B-containing lipoproteins in vivoH Kritz, H Sinzinger, G Lupattelli, et al.
Experimental Pathology|January 1, 1990
Additive benefit of PGI2 and PGE1 (via different mechanisms?) on inhibition of activation of human vascular smooth muscle cells?H Sinzinger, P Fitscha, O Wagner, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Journal of Cardiovascular Pharmacology|May 1, 1985
Transient drug-induced myocardial dysfunction is not ameliorated by PGI2 in dogsP Fitscha, G Krumpl, R Seitelberger, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|December 1, 1989
Beneficial effect of long-term PGE1-treatment in left ventricular heart failureI Virgolini, J Kaliman, P Fitscha, et al.
Prostaglandins|June 1, 1987
Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivoH Sinzinger, T Zidek, P Fitscha, et al.
Thrombosis Research|May 1, 1994
Isradipine decreases arterial thrombogenicity in rabbits. A morphometric and radioisotopic studyP Fitscha, A Keiler, J O'Grady, et al.
Fortschritte Der Medizin|February 3, 1977
[Pindolol as an antihypertensive agent]W F Pinggera, P Fitscha, H K Stummvoll, et al.
Prostaglandins, Leukotrienes, and Medicine|March 1, 1985
The prostacyclin synthesis stimulating plasma factor is unchanged during acute angina pectorisH Sinzinger, J Kaliman, P Fitscha, et al.
Prostaglandins|July 1, 1991
Intravenous prostacyclin (PGI2) infusion to 108 patients with ischaemic peripheral vascular disease: phase II-open studyI Virgolini, P Fitscha, K Weiss, et al.
Blood Pressure. Supplement|January 1, 1994
Isradipine increases platelet--low-density lipoprotein binding: evidence from ex-vivo studies in humansP Schmid, C Pirich, P Fitscha, et al.
European Journal of Clinical Pharmacology|January 1, 1997
Prostaglandin E1 decreases human arterial accumulation of radiolabeled apo B-containing lipoproteins in vivoH Kritz, H Sinzinger, G Lupattelli, et al.
Experimental Pathology|January 1, 1990
Additive benefit of PGI2 and PGE1 (via different mechanisms?) on inhibition of activation of human vascular smooth muscle cells?H Sinzinger, P Fitscha, O Wagner, et al.
Pageof 13